Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A 3-month placebo-controlled trial found that daily colchicine offered no meaningful pain relief over placebo in patients with knee osteoarthritis. Both groups saw significant pain score reductions, but the difference between them wasn't statistically significant. Notably, colchicine did reduce key inflammatory biomarkers, hinting at possible longer-term biological effects worth exploring.
A new placebo-controlled trial out of NYU Langone Health found that daily colchicine — a drug commonly used for gout and inflammation — did not outperform placebo in reducing knee pain or improving function in patients with knee osteoarthritis (OA). Both groups showed meaningful pain reductions over 3 months, but there was no statistically significant difference between them, even among patients with more severe symptoms or joint damage.
The study enrolled 120 participants (mean age 66.8 years) randomly assigned to receive colchicine or placebo for 3 months. Despite the null pain findings, colchicine was associated with significant reductions in high-sensitivity C-reactive protein and beta-nerve growth factor — two OA-related inflammatory biomarkers — suggesting the drug may still be producing meaningful biological changes.
Key Takeaways:
Why it matters: With few effective pharmacological options for knee OA, clinicians and researchers are actively looking for disease-modifying therapies. While colchicine won't replace current pain management strategies based on this data, its biomarker effects keep the door open for longer-term studies focused on structural outcomes.
